Key Findings from Treatment Algorithms: Rheumatoid Arthritis - Disease-Modifying Agents

Decision Resources, Inc, December 2011, Pages: 38

Physicians are increasingly initiating treatment with disease-modifying therapies for rheumatoid arthritis early in the course of the disease. Conventional, small molecule, disease-modifying antirheumatic agents (DMARDs) remain the mainstay of early-line treatment, but patients who fail such agents, patients with severe disease, or patients in whom conventional DMARDs are contraindicated are treated with biological DMARDs.

The most successful biological DMARDs in the RA market, TNF-a inhibitors, are threatened by several biological DMARDs with other mechanisms of action, which are experiencing strong uptake across multiple patient segments. Orencia (Bristol-Myers Squibb’s abatacept), Rituxan (Biogen Idec/Roche’s rituximab), and the recently launched Actemra (Roche’s tocilizumab) are competing for share among patients who fail TNF-a inhibitors, and marketers of each of these agents aim to carve out additional niches of TNF-a inhibitor-naive RA patients for whom they could be prescribed.

Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

1. Background
a) Publication Update
b) Report Contents and Features
c) Current Practice Guidelines
d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients
a) Executive Summary
b) Graphical Views
3. Key Findings for Recently Treated Patients
a) Executive Summary
b) Graphical Views

4. Key Findings by Product
a) Enbrel
b) Humira
c) Remicaide
d) Simponi
e) Cimzia
f) Orencia
g) Rituxan
h) Actemra
5. Appendix: Methodology

Customers who bought this item also bought

• Rheumatoid Arthritis (Event Driven)
• U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
• DRG Insight: Rheumatoid Arthritis (G7)
• Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
• What are European Physician and Payer Expectations for the Uptake of Emerging Oral Immunomodulators in Rheumatoid Arthritis?
• How Will New Entrants Alter the Biologics Landscape in Ankylosing Spondylitis and Psoriatic Arthritis? A European Physician and Payer Perspective
• Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
• Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
• Rheumatoid Arthritis Therapeutics Market in Thailand
• Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs